OBSV News and Press, ObsEva SA From 01/06/22

-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary end...

GENEVA, Switzerland January 3 , 202 2 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corpor...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll begin this penny stock list in the same manner that I begin all lists of penny stocks: With a caveat. Penny stocks are among the most volatile classes of investments. Pretty much everyone interested in this...

GENEVA, Switzerland December 20 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addition to the NASDAQ Biotechn...

Genfit (NASDAQ:GNFT) +39% inks licensing deal for elafibranor with Ipsen. Spruce Biosciences (NASDAQ:SPRB) +21%. Cerner (NASDAQ:CERN) +17% gains on report Oracle in talks to acquire for about $30B. Bottomline Technologies (NASDAQ:EPAY) +15% agrees to be taken pri...

ObsEva SA (NASDAQ:OBSV) announced that an expert panel of the European Medicines Agency (EMA) endorsed its oral GnRH antagonist linzagolix, recommending its approval for adult women with moderate to severe symptoms of uterine fibroids (UF). The positive opinion adopted by the EMA’s Com...

- European Commission Decision Anticipated in Q1 2022- - CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration - Ad hoc announcement pursuant to Art. 53 LR of ...

ObsEva (NASDAQ:OBSV) announces the appointment of Will Brown as Chief Financial Officer (CFO) and member of the company’s Executive Committee, effective January 1, 2022. Mr. Brown joins ObsEva from Altimmune where he served as CFO and was critical in the company’s transformation...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s rep...

- S ymposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- - 52-Week Da ta from the Phase 3 PRIMROSE stud ies ...